A Practical Analysis Of AstraZeneca Plc’s Dividend

Is AstraZeneca plc (LON: AZN) in good shape to deliver decent dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The ability to calculate the reliability of dividends is absolutely crucial for investors, not only for evaluating the income generated from your portfolio, but also to avoid a share-price collapse from stocks where payouts are slashed.

There are a variety of ways to judge future dividends, and today I am looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US) to see whether the firm looks a safe bet to produce dependable payouts.

Forward dividend cover

Forward dividend cover is one of the most simple ways to evaluate future payouts, as the ratio reveals how many times the projected dividend per share is covered by earnings per share. It can be calculated using the following formula:

Forward earnings per share ÷ forward dividend per share

City analysts expect AstraZeneca to produce a dividend of 181.3p in 2013, while earnings per share for this year are predicted to come in at 336.7p. This provides dividend cover of 1.9 times forward earnings, just below the widely-considered safety benchmark of 2 times.

Free cash flow

Free cash flow is essentially how much cash has been generated after all costs and can often differ from reported profits. Theoretically, a company generating shedloads of cash is in a better position to reward stakeholders with plump dividends. The figure can be calculated by the following calculation:

Operating profit + depreciation & amortisation – tax – capital expenditure – working capital increase

The pharmaceutical giant saw free cash flow dip to $2.07bn in 2012, down substantially from $7.83bn in 2011. The company suffered from a large dip in operating profit — to $8.15bn from $12.8bn — as patent expiries whacked revenues. Additionally, a massive hike in capex outlay, to $5.85bn from $2.62bn, also weighed on cash flow. This still outweighed a near-halving in tax costs, to $2.04bn from $4bn.

Financial gearing

This ratio is used to gauge the level debt a company carries. Simply put, the higher the amount, the more difficult it may be to generate lucrative dividends for shareholders. It can be calculated using the following calculation:

Short- and long-term debts + pension liabilities – cash & cash equivalents

___________________________________________________________            x 100

                                      Shareholder funds

AstraZeneca’s gearing ratio registered at 20.3% in 2012, up from 18.9% in 2011. The company saw debts rise to $10.31bn from $9.33bn in the prior 12-month period, although pension liabilities and cash and cash equivalents did improve — the latter increased to $7.7bn from $7.57bn. Still, an increase in shareholders’ equity, to $23.95bn from $23.47bn, helped stymie the gearing increase.

Buybacks and other spare cash

AstraZeneca has pledged to chuck vast amounts of capital into research and development in order to mitigate the rolling problem of patent expirations across its key products. The company announced in March its strategy to introduce innovation centres in the UK, Sweden and the US in order to bolster its product pipeline, although work is not expected to be completed until 2016.

In the meantime, the company remains hot in the M&A front, and last week announced that it had bought out New Jersey-based Omthera Pharmaceuticals, which develops therapies for abnormal lipid levels in the blood, for around $323m. This follows the purchase of Pearl Therapeutics late last month, which produces therapies for respiratory diseases. This deal could cost AstraZeneca as much as $1.15bn.

Big rewards but the risks are high…

AstraZeneca currently carries a dividend yield of 5.5% for 2013, far ahead of the prospective 3.3% FTSE 100 average. Although this clearly provides great opportunities to generate juicy dividend income, investors should be aware that the possibility of further earnings pressure could put the stops on future dividend growth.

Indeed, the pharma play kept last year’s full-year dividend on hold at 280 US cents as earnings took a 12% dive. I believe that the effect of eroding patent protection, coupled with the long wait times for its new R&D strategy to recharge its product pipeline, on the firm’s balance sheet could damage the dividend prospects moving forwards.

The inside track to hot stocks growth

If, like me, you do not like the look of AstraZeneca and are looking to significantly boost your investment returns elsewhere, check out this special Fool report, which outlines the steps you might wish to take in order to become a market millionaire.

Our “Ten Steps To Making A Million In The Market” report highlights how fast-growth small-caps and beaten-down bargains are all fertile candidates to produce ten-fold returns. Click here to enjoy this exclusive ‘wealth report’ — it’s 100% free and comes with no obligation.

> Royston does not own shares in AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Up 33%! Here’s why I’m not buying more Lloyds shares this month

Lloyds shares are on a tear in 2025, up almost a third since the year began. But Mark Hartley remains…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

£3,000 in savings? Here’s how it could be used to start investing and earning a monthly passive income

Christopher Ruane outlines how someone could start investing today with a spare £3K to try and build passive income streams…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Tesco shares go ex-dividend on 15 May. Time to consider buying them?

Harvey Jones admires Tesco shares because they combine solid share price growth with a decent level of dividend income. The…

Read more »

Senior couple are walking their dog through a public park in Autumn.
Investing Articles

Is today’s market turmoil a brilliant opportunity to get a high second income from dividends?

Falling share prices drive up yields in a boost for those after a second income from dividends. Harvey Jones looks…

Read more »

piggy bank, searching with binoculars
Investing Articles

Outlook: in just 12 months the BP share price could turn £10,000 into…

Forecasters seem pretty optimistic about prospects for the BP share price, suggesting it could be in for a major rally.…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Down 28%, is Nvidia stock a bargain – or a value trap?

Nvidia stock has crashed this year -- but it's still a star performer over the long term! So, is this…

Read more »

Investing Articles

£10k invested in Barclays shares at the start of 2025 is now worth…

Harvey Jones says Barclays shares were unlikely to continue 2024's blistering run, given all the uncertainty out there. Yet long-term…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Here’s how a first-time investor could start buying shares with £3k

Is it possible to start buying shares with £3K? Yes it is -- and here our writer goes into some…

Read more »